

1 **A primary care approach to the COVID-19 pandemic: clinical features and natural**
2 **history of 2,073 suspected cases in the Corona São Caetano programme, São Paulo,**
3 **Brazil**

4

5 Fabio E Leal^{1,2*#} (PhD), Maria C Mendes-Correa^{3*} (PhD), Lewis F Buss^{3*} (MBBS), Silvia F
6 Costa³ (PhD), Joao CS Bizario¹ (PhD), Sonia RP de Souza¹ (PhD), Osorio Thomaz⁴ (PhD),
7 Tania R Tozetto-Mendoza³ (PhD), Lucy S Villas-Boas³, Lea CO Silva³ (PhD), Regina MZ
8 Grespan (MD)¹, Ligia Capuani⁵ (PhD), Renata Buccheri³ (MD), Helves Domingues (PhD)⁵,
9 Neal DE Alexander⁶ (PhD), Philippe Mayaud⁶ (MD), Ester C Sabino³ (PhD)

10

11 * These authors contributed equally

12

13 **Affiliations**

- 14 1. Universidade Municipal de São Caetano do Sul (USCS), Rua Santo Antonio, São
15 Caetano do Sul, Brazil
16 2. National Cancer Institute (INCA), Praça Cruz Vermelha, Rio de Janeiro, Brazil
17 3. Instituto de Medicina Tropical (LIM-52, LIM-46, LIM-49) and Departamento de
18 Moléstias Infecciosas e Parasitárias da Faculdade de Medicina da Universidade de São
19 Paulo Avenida Dr. Enéas Carvalho de Aguiar, São Paulo, Brazil
20 4. Instituto de Pesquisas Tecnológicas do Estado de São Paulo - IPT
21 5. Modular Research System, Avenida Paulista, São Paulo, Brazil
22 6. London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London,
23 United Kingdom

24

25 **Corresponding author:**

26 # Prof Fabio E Leal

27 Faculdade de Medicina da Universidade Municipal de São Caetano do Sul

28 fabio.leal@inca.gov.br

29 +55 21 32076557

30

31

32 **KEY WORDS:** SARS-CoV-2, COVID-19, pandemic, community, primary care, Brazil

33

34

35 **ABSTRACT**

36

37 **Background:** Despite most cases not requiring hospital care, there are limited community-
38 based clinical data on COVID-19.

39 **Methods and findings:** The Corona São Caetano program is a primary care initiative
40 offering COVID-19 care to all residents of São Caetano do Sul, Brazil. After triage of
41 potentially severe cases, consecutive patients presenting between 13th April and 13th May
42 2020 were tested at home with SARS-CoV-2 reverse transcriptase (RT) PCR; positive
43 patients were followed up for 14 days. RT-PCR-negative patients were offered SARS-CoV-2
44 serology. We describe the clinical features, virology and natural history of this prospective
45 population-based cohort. Of 2,073 suspected COVID-19 cases, 1,583 (76.4%) were tested by
46 RT-PCR, of whom 444 (28.0%, 95%CI: 25.9% - 30.3%) were positive; 604/1,136 (53%) RT-
47 PCR-negative patients underwent serology, of whom 52 (8.6%) tested SARS-CoV-2
48 seropositive. The most common symptoms of COVID-19 were cough, fatigue, myalgia and
49 headache; whereas self-reported fever, anosmia, and ageusia were most associated with a
50 positive COVID-19 diagnosis. RT-PCR cycle thresholds were lower in men, older patients,
51 those with fever and arthralgia, and around symptom onset. The rates of hospitalization and
52 death among 444 RT-PCR-positive cases were 6.7% and 0.7%, respectively, with older age
53 and obesity more frequent in the hospitalized group.

54 **Conclusions:** COVID-19 presents similarly to other mild respiratory disease in primary care.
55 Some symptoms assist the differential diagnosis. Most patients can be managed at home.

56

57

58

59

60

61

62

63

64

65

66

67

68

69 **INTRODUCTION**

70

71 A comprehensive public health response is vital but difficult to achieve during an epidemic.
72 The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome
73 coronavirus 2 (SARS-CoV-2), started in China in late 2019.¹ According to the World Health
74 Organization (WHO)² and others³, the ideal early response should have been multipronged,
75 with identification, isolation, treatment and contact tracing of symptomatic cases, relying on a
76 strong testing programme. Primary health care (PHC) is well placed to implement such a
77 response, by identifying cases early and managing them in a way that minimizes
78 overcrowding of emergency rooms and intensive care units.⁴ Real-time data analysis coming
79 from these primary care response systems can inform policy decisions.

80

81 In Brazil, the first case of COVID-19 was identified in the city of São Paulo on 26th February
82 2020.⁵ As of 15th June 2020 there were 867,000 cases nationally with São Paulo contributing
83 a fifth of these.⁶ In March 2020, the Municipal Health Department of the municipality of São
84 Caetano do Sul – part of the Greater Metropolitan Region of São Paulo – began to develop a
85 clinical and testing platform to organize its COVID-19 response. The aim was to provide
86 universal detection and management of symptomatic cases and their contacts. The platform
87 was developed in partnership with two local universities – the Municipal University of São
88 Caetano do Sul (USCS) and the University of Sao Paulo (USP) – and called “Corona São
89 Caetano”.

90

91 Large scale community-based observational cohorts are difficult to establish under epidemic
92 circumstances, particularly if the risk of exposure for research personnel is high. Hence, most
93 COVID-19 epidemiological and clinical studies have been hospital-based,⁷⁻⁹ and therefore
94 tend to include more severe cases whose findings may not be generalizable to the general
95 population.¹⁰ The objectives of this study were to describe the epidemiological indicators of
96 the early phase of the programme rollout; and to describe the clinical, virologic and natural
97 history features (including hospitalization and deaths) of SARS-CoV-2 infection among
98 patients identified in primary care.

99

100

101

102

103 **METHODS**

104

105 **Setting**

106

107 The municipality of São Caetano do Sul has a population of 161,000 inhabitants.¹¹ The active
108 aging index (i.e., the ratio of population aged >60 yr / population aged ≤14 yr) is 135,
109 compared to the Brazilian average of 52, reflecting an aging population;¹¹ its Human
110 Development Index is one of the highest in the country; nearly all (97.4%) children aged 6-14
111 are in education and 31% of the population have completed higher education¹² (Brazilian
112 national average is 11%).

113

114 **Corona São Caetano platform**

115

116 Residents of the municipality aged 12 years and older with suspected COVID-19 symptoms
117 were encouraged to contact the dedicated Corona São Caetano platform via the website
118 (access at <https://coronasaocaetano.org/>) or by phone. They were invited to complete an
119 initial screening questionnaire that included socio-demographic data; information on
120 symptoms type, onset and duration; and recent contacts.

121

122 Patients meeting the suspected COVID-19 case definition (i.e., having at least two of the
123 following symptoms: fever, cough, sore throat, coryza, or change in/loss of smell (anosmia);
124 or one of these symptoms plus at least two other symptoms consistent with COVID-19) were
125 further evaluated, whilst people not meeting these criteria were reassured, advised to stay at
126 home and contact the service again if they were to develop new symptoms or worsening of
127 current ones. Patients were then called by a medical student to complete a risk assessment.
128 All pregnant women, and patients meeting pre-defined triage criteria for severe disease (see
129 Supplemental Material), were advised to attend a hospital service - either an emergency
130 department or outpatient service, depending on availability. All other patients were offered a
131 home visit for self-collection of a nasopharyngeal swab.

132

133 **Sample collection**

134

135 Nasopharyngeal swabs (NPS – both nostrils and throat) were collected at the patients' homes
136 under the supervision of trained healthcare personnel. A link to a video

137 (<https://youtu.be/rWZzV2ZP7KY>) was sent to the patients, before the home visit, to provide
138 guidance on self-collection procedures. Healthcare personnel were instructed to maintain a
139 distance of six feet from the patient and to wear personal protective equipment at all times.
140 Samples were immediately put on a cool box between 2-8°C and stored at 4°C in a fridge
141 until shipment to the lab within 24 hours.

142

143 **Follow-up procedures**

144

145 Patients testing SARS-CoV-2 RT-PCR positive were followed up to 14 days (a maximum of
146 7 phone calls) from completion of their initial questionnaire. They were contacted every 48
147 hours by a medical student who completed another risk assessment and recorded any ongoing
148 or new symptoms. Patients testing RT-PCR negative were followed up by the primary health
149 care program for their residential area. They were advised to contact the platform for a new
150 consultation if they developed new symptoms. Starting on May 19th, when serological
151 testing became available, RT-PCR-negative patients were re-contacted to offer antibody
152 (IgG/IgM combined) testing 14 days after their initial registration as long as they had become
153 asymptomatic.

154

155 **Study dates**

156

157 The Corona São Caetano programme was launched on 6th April 2020 and is still ongoing at
158 the time of writing. For this analysis, we opted to include all patients making their first
159 contact with the programme between 13th April and 13th May 2020. This comprises the first
160 31 days of the response, having excluded the first week, which corresponded to a pilot phase
161 designed to test instruments before roll-out. The period of follow-up (last date of data
162 extraction) was 4th June 2020, to account for the accrual period (three weeks) of possible
163 hospitalizations in the last included patients.

164

165 **Laboratory methods**

166

167 Due to shortages of some reagents, two RT-PCR platforms were used at different times
168 during the study: ALTONA RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Hamburg, Germany)
169 and the Mico BioMed RT-qPCR kit (Seongnam, South Korea). For serology we tested 10µL
170 of serum or plasma (equivalent in performance) using a qualitative rapid chromatographic

171 immunoassay (Wondfo Biotech Co., Guangzhou, China), that jointly detects anti-SARS-
172 CoV-2 IgG/IgM. The assay has been found to have a sensitivity of 81.5% and specificity of
173 99.1% in a US study¹³. In our local validation, after two weeks of symptoms, the sensitivity
174 in 59 RT-PCR confirmed cases was 94.9%, and specificity in 106 biobank samples from
175 2019 was 100%.

176

177 **Statistical methods**

178

179 We estimated the contribution of our primary platform to COVID-19 diagnosis in São
180 Caetano do Sul. We compared the number of cases diagnosed in our programme with official
181 data released by the Municipal Department of Health in its daily bulletins (accessed here
182 <https://coronavirus.saocaetanodosul.sp.gov.br>).

183

184 Clinical and demographic data were extracted directly from the Corona São Caetano
185 information system, with the last export on 5th June, to allow for follow-up of patients at the
186 end of the study period. To analyse clinical presentation, we first calculated the proportion
187 and exact binomial 95% confidence intervals (CI) of cases reporting each symptom in the
188 three testing groups: SARS-CoV-2 RT-PCR positive; RT-PCR negative / seropositive; and
189 RT-PCR negative / seronegative. We next combined RT-PCR and serology positive cases to
190 make confirmed COVID-19 group, and those negative on both tests to make a SARS-CoV-2
191 negative control group. We express the association between each symptom and a positive
192 COVID-19 diagnosis as odds ratios (OR) and 95% CIs. For RT-PCR-positive patients, we
193 grouped the follow-up questionnaire responses into two-day intervals from symptom onset.
194 In order to illustrate symptom trajectories through time, we calculated the proportion of
195 questionnaire responses where a given symptom was present for each time window.

196

197 Next, we assessed associations between RT-PCR cycle thresholds (Cts) and other clinical
198 features. ALTONA and MiCo BioMed RT-PCR kits each separately amplify two different
199 SARS-CoV-2 viral genes, as such each patient had two Ct values. There was a high
200 concordance between Cts for the two genes within each kit (Figure S4), and we opted
201 therefore to use the mean of the two Ct values for each patient in all analyses. We calculated
202 univariable associations between Cts and age, sex, delay from symptom onset to NPS
203 collection, and presenting symptoms using simple linear regression. We then built a
204 multivariable linear regression model to assess independent associations between presenting

205 symptoms and RT-PCR Cts. As age, sex, and time of swab collection may confound this
206 relationship we included these variables, as well as the RT-PCR platform (ALTONA vs
207 MiCo BioMed), as covariates in the model.

208

209 For RT-PCR positive patients (followed up for 14 days), hospitalizations and deaths were
210 extracted from the study platform. To extend the follow-up period and to capture RT-PCR
211 negative patients and those initially triaged to hospital (no study follow-up), hospitalization
212 and vital status was confirmed by linkage with two administrative databases: the municipal
213 epidemiological surveillance dataset, as well as the state-wide influenza-like illness
214 notification system (SIVEP-Gripe). Linkage was last performed on 5th June 2020, 23 days
215 after the last patient was enrolled. Categorical patient characteristics were compared
216 according to hospitalization status using a Chi-squared or Fisher exact test. Continuous
217 variables were compared using the Wilcoxon rank sum test.

218

219 The cohort sample included consecutive cases presenting to the Corona São Caetano program
220 and a formal sample size calculation was not performed. Missing data were excluded. All
221 analyses were conducted in R Software for Statistical Computing, version 3.6.3.¹⁴

222

223 **Ethics**

224

225 The study was approved by the local ethics committee (Comissão de Ética para Análise de
226 Projeto de Pesquisa - CAPPesq, protocol No. 13915, dated June 03, 2020). The committee
227 waived the need for informed consent and allowed the development of an analytical dataset
228 with no personal identification for the current analysis.

229

230 **Role of the funding source**

231

232 The funder had no role in the collection, analysis, or interpretation of data; nor in the writing
233 of the report or the decision to submit the paper for publication. The corresponding author
234 had full access to the data and ultimate decision to submit the manuscript.

235

236

237

238

239 **RESULTS**

240

241 **Epidemiological and programmatic indicators**

242

243 Between 13th April and 13th May 2020, there were 2,073 presentations, from 2,011 individual
244 patients, that met the criteria for a suspected COVID-19 case. At initial phone interview, 132
245 (6%) potential cases were advised to go directly to a health service based on the triage
246 questions, and 12 (0.6%) because of pregnancy. Only four (3%) of referred patients were
247 admitted to hospital and none died.

248

249 In total 1,583 individual patients were tested with RT-PCR for SARS-CoV-2; 444 (28.0%,
250 95%CI 25.9%-30.3%) were positive. The proportion of positive results was stable over the
251 study (Figure S1). Among the RT-PCR negative group, 604 (53% of 1,136) underwent
252 serology testing, of whom 52 (8.6%, 95%CI 6.6% - 11.1%) were seropositive. The median
253 [IQR] time from symptom onset to serology collection was 31 [26 – 37] days. The age-sex
254 structure of patients being tested differed from the underlying population of São Caetano do
255 Sul (Figure S2) with an overrepresentation of working-age adults and women. At the
256 beginning of programme roll out, 75% of notified COVID-19 cases in São Caetano do Sul
257 were diagnosed in outpatient or hospital services. Over the study period, adherence to the
258 programme increased, and by May 13th, 2020, 78% of cases in the municipality were
259 diagnosed within our programme.

260

261 Of 444 RT-PCR positive patients eligible for longitudinal follow-up, 326 (73%) had their
262 final follow-up visit at least 14 days after their initial presentation. Of the seven possible
263 follow-up questionnaires, 384 (86%) COVID-19 patients completed three or more, and 162
264 (36%) completed all seven.

265

266 **Participant characteristics**

267

268 Patient characteristics are shown in Table 1. Although women were overrepresented in the
269 cohort, there were proportionally more males in the RT-PCR positive and seropositive groups
270 compared to the seronegative group. Of note, 55% of RT-PCR negative/seronegative patients
271 had completed higher education compared to 35% RT-PCR-positive patients ($p < 0.001$, Chi-
272 squared test). The median number of days from symptom onset to swab collection was 5.0

273 (interquartile range [IQR], 4·0-7·0) among RT-PCR positive patients and 6·0 (IQR, 4·0-8·3)
 274 among RT-PCR negative/seropositive patients (p = 0·06, Wilcoxon rank sum) (Figure S3).
 275 Chronic respiratory disease was less frequent in RT-PCR positive than dual-negative patients.
 276

277 **Table 1** Demographic and clinical characteristics of 1,048 suspected COVID-19 cases
 278 undergoing diagnostic testing in the Corona São Caetano program

	RT-PCR +ve (G1) N = 444 n (%) or median (IQR)	RT-PCR -ve Sero +ve (G2) N=52 n (%) or median (IQR)	RT-PCR -ve Sero -ve (G3) N = 552 n (%) or median (IQR)	p-value G1 versus G2	p-value G1 versus G3
Sex					
Male	200 (45·0)	23 (44·2)	185 (33·5)	1·0	<0·001
Female	244 (55·0)	29 (55·8)	367 (66·5)		
Age groups (years)					
10 to 19	29 (6·5)	1 (1·9)	25 (4·5)	0·07	0·40
20 to 39	197 (44·4)	17 (32·7)	236 (42·8)		
40 to 59	158 (35·6)	28 (53·8)	218 (39·5)		
60+	60 (13·5)	6 (11·5)	73 (13·2)		
Educational level					
Up to primary education	75 (16·9)	7 (13·5)	56 (10·2)	0·10	<0·001
High school	214 (48·3)	19 (36·5)	194 (35·2)		
University	154 (34·8)	26 (50·0)	301 (54·6)		
Essential Occupation					
Non-HCW essential job *	137 (30·9)	12 (23·1)	148 (26·9)	0·45	0·01
Carers	10 (2·3)	0 (0·0)	8 (1·5)		
HCW	32 (7·2)	5 (9·6)	73 (13·2)		
No	264 (59·6)	35 (67·3)	322 (58·4)		
Body mass index (kg/m²)					
<25	151 (34·2)	22 (42·3)	211 (38·4)	0·62	0·14
25-29	182 (41·2)	17 (32·7)	187 (34·0)		
30-35	79 (17·9)	9 (17·3)	112 (20·4)		
35+	30 (6·8)	4 (7·7)	40 (7·3)		
Comorbidities					
Cardiovascular disease	88 (20·4)	9 (17·6)	129 (24·0)	0·89	0·40
Diabetes mellitus	48 (11·1)	4 (7·8)	39 (7·3)	0·86	0·12
Any chronic resp. disease	37 (8·9)	9 (18·0)	79 (15·3)	0·13	0·01
COPD	24 (5·5)	5 (9·8)	54 (10·1)	0·47	0·03
Chronic kidney disease	1 (<1)	0 (0·0)	3 (1·0)	1·0	0·83
Time from symptom onset to swab collection (days), median (IQR)	5·0 (4·0-7·0)	6·0 (4·0-8·3)	6·0 (4·0-9·0)	0·06	<0·001

279 * Security, emergency services, supermarket, public transport, and pharmacy workers. IQR: interquartile range;
 280 HCW: health care workers, COPD: chronic obstructive pulmonary disease. Missing data – educational level 2;
 281 essential occupation 2; body mass index 4; cardiovascular disease 28; diabetes 31 mellitus; chronic resp. disease
 282 65; chronic kidney disease 27; COPD 28. P-values calculated by Chi-squared, Fisher exact, or Wilcoxon rank
 283 sum.

284 **Symptoms of COVID-19 at cohort presentation**

285

286 The prevalence of individual symptoms at presentation is shown in Figure 2A stratified by
287 final diagnostic category. The most frequent symptoms among RT-PCR and seropositive
288 patients were headache (82% and 75%), myalgia (80% and 80%), cough (77% and 63%), and
289 fatigue (77% and 79%) (Figure 3). Anosmia was present in 56% and 63% of RT-PCR
290 positive and seropositive patients, respectively, compared to 30% in those testing doubly
291 negative. A similar pattern was observed for ageusia (53% and 53% versus 30%).

292

293 The odds ratios for testing positive for SARS-CoV-2 (RT-PCR or serology) associated with
294 each presenting symptom are shown in Figure 3. The symptoms with strongest associations
295 were anosmia (OR 3.3, 95%CI 2.6-4.4), fever (3.0, 95%CI 2.4-3.9) and ageusia (2.9, 95%CI
296 2.3-3.8). The presence of sore throat (0.53, 95%CI 0.41-0.68) and diarrhoea (0.72, 95%CI
297 0.55-0.96) were associated with a negative SARS-CoV-2 test.

298

299 Among RT-PCR positive or seropositive patients, in general, younger patients presented with
300 more symptoms, with mean [standard deviation] number of symptoms of 8.33 [1.92], 8.24
301 [2.39], 8.09 [2.46] and 7.05 [2.54], in those aged 12 to 19 years, 20 to 39 years, 40 to 59
302 years, and 60+ years, respectively ($p=0.008$, Kruskal-Wallis test). In particular, upper
303 respiratory tract symptoms - including coryza, blocked nose, ageusia, and anosmia - were
304 more frequent in younger people (Figure 2B). The mean [sd] number of symptoms was
305 greater in women (8.28 [2.41]) than men (7.72 [2.45]) ($p=0.005$, Wilcoxon rank sum)
306 (Figure 2C).

307

308 **Symptoms over time in SARS-CoV-2 RT-PCR positive patients**

309

310 Figure 4 presents the symptom questionnaire responses over time for 444 RT-PCR positive
311 patients. In general, constitutional symptoms – in particular fever, arthralgia, and myalgia –
312 were prominent at symptom onset, with a large drop in the proportion reporting these
313 symptoms after four to six days. By contrast, anosmia, and ageusia were most frequent
314 among questionnaire responses at four to eight days and continued to be reported later in the
315 illness course. Cough was highly prevalent at disease onset, with a third of questionnaires
316 completed at 14 to 16 days positive for cough.

317

318 **Associations between SARS-CoV-2 RT-PCR Cycle threshold (Ct) values, and**
319 **demographic and clinical features**

320

321 Figure 5 shows the associations between mean RT-PCR cycle threshold and demographic
322 features and symptoms at presentation. Older age was associated with lower cycle thresholds,
323 with a change in mean Ct of -0.05 (95%CI -0.09 to -0.01) for each additional year of age. The
324 mean difference in Ct value was -1.36 (95% CI -2.49 to -0.23) in men compared to women.
325 For each doubling in the number of days from symptom onset to swab collection the mean Ct
326 value increased by 3.28 (95%CI 2.33 to 4.03). Presenting symptoms of fever and arthralgia
327 were associated with lower Cts, whereas anosmia, ageusia, vomiting, diarrhoea, and nausea
328 were associated with higher Cts (Figure 6 and Table S1). After adjustment for age, sex, delay
329 from symptom onset, and RT-PCR platform used, fever (-0.06, 95%CI -2.11 to -0.001) and
330 arthralgia (-1.24, -2.18 to -0.10) remained associated with lower Cts, and anosmia (2.21, 1.0
331 to 3.29), ageusia (1.96, 0.88 to 3.0), and diarrhoea (1.36, 0.12 to 2.61) with higher Cts
332 (Table S1).

333

334 **Hospitalizations and deaths**

335

336 Of the 444 RT-PCR positive patients, 30 (6.8%) had been hospitalized by 5th June 2020,
337 when the database linkage was last updated, and three (0.7%) had died; in-hospital mortality
338 was therefore 10% (3/30). In 28 cases the date of admission was available. The median time
339 from symptom onset to hospital admission was 7 (range 2 to 14) days. Among 1,136 RT-
340 PCR-negative patients, six (0.5%) had been admitted to hospital. One (<0.01% of 1,136) of
341 these six patients died. None of the 604 RT-PCR negative patients that underwent serology
342 were admitted to hospital or died. Table 2 compares patient characteristics by hospitalization
343 status. Notably, hospitalized patients were older, had more cardiovascular comorbidities and
344 were more frequently obese.

345

346

347

348

349

350

351

352 **Table 2** Characteristics of RT-PCR positive patients stratified by hospitalization status.

	Hospitalized n=30 n (%) or median (IQR)	Not hospitalized n=414 n (%) or median (IQR)	p-value
Age (years)			
10 to 19	1 (3)	28 (97)	
20 to 39	6 (3)	191 (97)	
40 to 59	14 (9)	144 (91)	
60+	9 (15)	51 (85)	0.006
Sex			
Female	16 (7)	228 (93)	
Male	14 (7)	186 (93)	0.852
Comorbidities			
Cardiovascular disease	11 (13)	77 (87)	0.001
Diabetes mellitus	8 (17)	40 (83)	0.007
Any chronic resp. disease	2 (5)	35 (95)	1.0
COPD	1 (5)	23 (95)	1.0
Chronic kidney disease	1 (100)	0 (0)	0.06
Body mass index (Kg/m²)			
<25	4 (3)	147 (97)	
25-29	8 (4)	174 (96)	
30-35	12 (15)	67 (85)	
35+	6 (20)	24 (80)	<0.001
Time to presentation (days)	3 (3 to 4)	4 (3 to 5)	0.072

353 Missing data – body mass index 2; cardiovascular disease 12; diabetes mellitus 12; chronic respiratory disease
 354 29; COPD 11; chronic kidney disease 12; COPD - chronic obstructive pulmonary disease; IQR - interquartile
 355 range.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370 **DISCUSSION**

371

372 We present a community-based cohort of suspected COVID-19 cases recruited through a
373 primary care initiative in the Brazilian municipality of São Caetano do Sul. Offering RT-PCR
374 testing to all patients presenting with symptoms compatible with COVID-19, the positivity
375 rate was 28%, with 8.6% of those testing negative subsequently found to be seropositive - i.e.
376 > 35% of the cohort had a diagnosis of COVID-19. Anosmia, ageusia, and self-reported fever
377 provided the greatest diagnostic value in identifying COVID-19. The rate of hospitalization
378 and deaths among RT-PCR positive patients was low, at 6.8% and 0.7%, respectively. Our
379 results provide important information on the clinical presentation, diagnostic testing and
380 natural history of COVID-19 identified in the community.

381

382 Extrapolating the seropositivity rate among RT-PCR negative patients to the 532 that were
383 not tested with serology, we estimate that an additional 46 seropositive cases would have
384 been identified. This corresponds to a false-negative rate of 18% among potential
385 symptomatic COVID-19 cases. This is lower than a recent pooled analysis: nadir of 20% at
386 three days post-symptom onset.¹⁵ Viral load peaks around the time of symptom onset and
387 remains high over the first symptomatic week (also see Figure 5A).^{16,17} Consistent with this,
388 we found a slightly longer delay to swab collection in RT-PCR false-negative patients than
389 RT-PCR positive patients (Figure S4).

390

391 COVID-19 presents in a similar way to other respiratory viral illnesses. Indeed, in our cohort
392 the most common symptoms of COVID-19 - such as cough, fatigue, headache, etc. - were
393 reported with a similar frequency among patients testing negative. It is therefore important to
394 have identified anosmia, ageusia, self-reported fever, myalgia, and anorexia as the symptoms
395 with greatest value in the differential diagnosis of COVID-19 in primary care. Conversely,
396 sore throat and diarrhoea - both considered symptoms of COVID-19 in other settings -¹⁸
397 were more frequently due to other aetiologies in this primary care context. These results are
398 robust for a number of reasons. Firstly, our sample is representative of the population of
399 interest - i.e. consecutive patients with suspected COVID-19 in the community - instead of
400 extrapolating from hospital cases. Symptom data were collected prospectively, eliminating
401 recall or interviewer bias. Finally, we have a control group of patients who were negative for
402 both RT-PCR and serology, minimizing misclassification due to false negative RT-PCR.

403

404 In our study, the proportion of patients with a positive SARS-CoV-2 RT-PCR requiring
405 hospitalization was low (7%). Early reports from China were of 13·8% of cases being
406 severe¹⁹, but this value was lower when under ascertainment of cases was accounted for.^{20,21}
407 This is because our cohort reflects mild to moderate cases, as severely ill patients are likely to
408 have attended hospital directly. As such, only 3% of patients we triaged to attend health
409 services were ultimately hospitalized, possibly due to self-selection of patients presenting to
410 our service. Supporting this notion, our overall case fatality ratio among RT-PCR positive
411 patients was 0·7%.

412

413 Our study has some limitations. Serology was not performed on all RT-PCR negative patients
414 due to on-going symptoms, loss to follow-up, or patient refusal. Of note, none of the RT-
415 PCR-negative patients that were admitted to hospital underwent serology testing. This
416 suggests that patients who were not tested with serology may have had a higher prevalence of
417 COVID-19 than those that were tested. In addition, imperfect serology test performance
418 (81% sensitivity)¹³ will introduced false-negative results. Taken together, these biases may
419 have underestimated the true seroprevalence among RT-PCR-negative cases, as well as the
420 false-negative rate of RT-PCR. The latter calculation may also have been influenced by the
421 inclusion of RT-PCR positive patients in the denominator, introducing an incorporation bias.²²

422

423 A key strength to our study relates to the provision of primary healthcare in Brazil and its
424 symbiosis with medical training nationwide. Primary health care - within the family health
425 strategy (*Estratégia Saúde da Família*) - is cantered around a healthcare unit with a multi-
426 professional team that is responsible for all residents in the immediate catchment area²³. São
427 Caetano do Sul has 100% coverage with the family health strategy, and medical students
428 from the municipal university (USCS) are integrated into the healthcare teams and
429 progressively trained from the first year of medical school. Our initiative took advantage of
430 this existing system, with the addition of an online platform allowing remote clinical
431 assessment and follow-up. The suspension of normal clinical training at the medical school
432 provided the workforce. The partnership with the University of São Paulo, which provided
433 the laboratory diagnostics, created the unique opportunity to establish our prospective
434 community cohort of suspected and confirmed COVID-19 cases. But we believe that this
435 infrastructure can be implemented in other regions with less resources, now understanding
436 the key steps and problems in the implementation. The second phase of the platform is now

437 focusing on contact tracing from index cases identified by molecular or serological testing,
438 using a rapid response team and rapid serological testing.

439

440 As in most places around the globe, the Brazilian National Health System is underfunded.
441 Nevertheless, the fact that primary health care infrastructure is well established in many areas
442 in Brazil, would allow the rapid deployment of similar strategies, and at low cost. A primary
443 healthcare approach to the COVID-19 pandemic using a bespoke computer platform and
444 telehealth to control the activities has been paramount to properly delineate the characteristics
445 and dynamics of the disease at community level and plan a multifaceted public health
446 response accordingly. Other respiratory disease such as influenza, measles, or tuberculosis
447 may benefit from similar infrastructure.

448

449 **AUTHOR CONTRIBUTIONS**

450

451 FL, MC, SC, MC, RB, and ES conceived and designed the study. FL, RG, and JB provided
452 clinical oversight and supervision of medical students. FL, MC, LB, HD, and SS collected
453 and curated the data. MC, TM, LV, and LS performed the laboratory analysis. LB performed
454 the formal statistical analysis with assistance from FL, SS, NA, PM, ES. LB, FL, PM and ES
455 wrote the first draft, and all authors reviewed, contributed to and approved the final version.

456

457 **CONFLICTS OF INTEREST**

458

459 The authors have no conflicts of interests.

460

461 **ACKNOWLEDGMENTS**

462

463 The municipal health department of São Caetano do Sul (Secretaria Municipal de Saúde da
464 Prefeitura de São Caetano do Sul) funded the establishment and implementation of the
465 platform. We also acknowledge an award from FAPESP (2018/14389-0) and the UK Medical
466 Research Council (MR/S0195/1) to the Brazil-UK Centre for Arbovirus Discovery,
467 Diagnosis, Genomics and Epidemiology (CADDE).

468

469

470

471

472 REFERENCES

- 473
- 474 1 World Health Organization. (2020). Pneumonia of unknown cause – China.
475 (<https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/>,
476 accessed 2020-06-18).
- 477 2 World Health Organization. Critical preparedness, readiness and response actions for
478 COVID-19 (Interim Guidance) ([https://www.who.int/publications-detail/critical-](https://www.who.int/publications-detail/critical-preparedness-readiness-and-response-actions-for-covid-19)
479 [preparedness-readiness-and-response-actions-for-covid-19](https://www.who.int/publications-detail/critical-preparedness-readiness-and-response-actions-for-covid-19), accessed 15 June 2020).
- 480 3 Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19
481 outbreaks by isolation of cases and contacts. *Lancet Glob Health* 2020; 8: e488–96.
- 482 4 World Health Organization. Regional Office for the Western Pacific. (2020). Role of
483 primary care in the COVID-19 response. (<https://apps.who.int/iris/handle/10665/331921>,
484 accessed 15 June, 2020).
- 485 5 World Health Organization. Situation report 27 (2020).
486 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>,
487 accessed 15 June 2020).
- 488 6 Brazilian Ministry of Health. (<https://covid.saude.gov.br/>, accessed 15 June 2020).
- 489 7 Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
490 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
491 prospective observational cohort study. *BMJ* 2020; m1985.
- 492 8 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
493 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
494 New York City Area. *JAMA* 2020; **323**: 2052.
- 495 9 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
496 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**:
497 1054–62.
- 498 10 Rauh AL, Linder JA. Covid-19 care before, during, and beyond the hospital. *BMJ*
499 2020; m2035.
- 500 11 Instituto Brasileiro de Geografia e Estatística (IBGE). (2020). São Caetano do Sul /
501 Panorama. (<https://cidades.ibge.gov.br/brasil/sp/sao-caetano-do-sul/panorama>, accessed 20
502 June 2020).
- 503 12 Human Development Atlas Brazil. (2020). São Caetano do Sul
504 (http://atlasbrasil.org.br/2013/pt/perfil_m/sao-caetano-do-sul_sp, accessed 20 June 2020).
- 505 13 Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-
506 2 serological assays. *medRxiv* 2020; 2020.04.25.20074856.
- 507 14 R Core Team. R: A language and environment for statistical computing. R
508 Foundation for Statistical Computing, Vienna, Austria. (<https://www.R-project.org/>. 2019).
- 509 15 Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-
510 Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2
511 Tests by Time Since Exposure. *Ann Int Med* 2020; M20-1495.
- 512 16 To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in
513 posterior oropharyngeal saliva samples and serum antibody responses during infection by
514 SARS-CoV-2: an observational cohort study. *Lancet Inf Dis* 2020; **20**: 565–74.
- 515 17 He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and
516 transmissibility of COVID-19. *Nat Med* 2020; **26**: 672–5.
- 517 18 Vetter P, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquieroz F. Clinical features
518 of covid-19. *BMJ* 2020; m1470.
- 519 19 T. Team, Vital Surveillances: The Epidemiological Characteristics of an Outbreak of
520 2019 Novel Coronavirus Diseases (COVID-19)-China. *China CDC Weekly* 2020; **2**: 113–22.

- 521 20 Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in
522 France. *Science* 2020; eabc3517.
- 523 21 Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease
524 2019: a model-based analysis. *Lancet Infect Dis* 2020; **20**: 669–77.
- 525 22 Worster A, Carpenter C. Incorporation bias in studies of diagnostic tests: how to
526 avoid being biased about bias. *CJEM* 2008; **10**: 174–5.
- 527 23 Macinko J, Harris MJ. Brazil’s Family Health Strategy — Delivering Community-
528 Based Primary Care in a Universal Health System. *NEJM* 2015; **372**: 2177–81.

529
530
531

532 **FIGURE LEGENDS**

533

534 **Figure 1** Patient flowchart for the Corona São Caetano platform between 13th April and 13th
535 May 2020. In the upper section (white background) the numbers correspond to individual
536 presentations to the system; among suspected cases 2,073 suspected cases, 60 had two
537 presentations and one had three. In the lower section (grey background) numbers correspond
538 to individual patients making up the final analytic groups.

539

540 **Figure 2** Panel A present prevalence (point) and exact binomial 95% confidence intervals
541 (vertical lines) of symptoms at presentation among patients with suspected COVID-19
542 according to RT-PCR result and serostatus (A). Panels B and C present the prevalence of
543 presenting symptoms among patients with COVID-19 (RT-PCR and serology positive)
544 stratified by age (B) and sex (C).

545

546 **Figure 3** Odds ratios (black dot) and 95% confidence intervals (lines) for testing positive for
547 COVID-19 (RT-PCR positive or serology positive) associated with the presence of each
548 presenting symptom. Horizontal axis is on log scale. Point estimates of odds ratios are shown
549 inline with their corresponding symptom.

550

551 **Figure 4** Left hand figures show symptoms at each follow-up questionnaire among patients
552 testing RT-PCR positive and undergoing follow-up. Individual patients are stacked on the y-
553 axis ordered according to the delay from symptom onset to presentation. Each point
554 represents the response to a questionnaire and its position on the horizontal axis the time after
555 symptom onset that the questionnaire was filled in. Grey points are questionnaires where the
556 patient denied the presence of a given symptom. The coloured points correspond to
557 questionnaires in which the patient reported a given symptom. The right-hand figures results
558 from grouping the horizontal axis time into two-day windows and calculating the proportion

559 of completed questionnaires in which each symptom was reported. The denominators for the
560 horizontal axis groups (number of questionnaires completed within a given time window
561 from symptom onset) are 104 at [0-2] days, 192 at (2-4], 185 at (4-6], 293 at (6-8], 338 at (8-
562 10], 329 at (10-12], 335 at (12-14], 324 at (14-16], 280 at (16-18] and 201 at (18-20].

563

564 **Figure 5** Relationship between mean RT-PCR cycle threshold (Ct) and day of illness course
565 when the nasopharyngeal swab was collected (A), patient age (B), patient sex (C), and
566 different symptoms at presentation. Panels A and B show the best fit linear regression lines,
567 panels C and D are violin plots (rotated kernel density plots showing the full distribution of
568 data) of the Ct values with median (black dot) and interquartile range (black line).

569

570

Initial questionnaires filled in
n = 2582

Not meeting suspected case definition (n = 509)

Suspected COVID-19 cases
n = 2073

Suspected cases not tested (n = 479)
Sent to hospital – alarm signs: 132
Sent to hospital – pregnant: 12
Lost contact before home visit: 335

PCR tests performed
n = 1594

Patients tested more than once (n = 11)
Two separate negative results: 8
First PCR negative, second PCR positive (included as PCR positive case): 3

Episodes of care

Individual patients

Patients tested with PCR
n = 1583

PCR-inconclusive patients
n = 3

PCR-positive patients
n = 444


PCR-negative patients
n = 1136

Not tested for serology (n = 532)
Still symptomatic 34
Refused 168
Contact/collection not achieved by end of study period 330


Seropositive
n = 52

Seronegative
n = 552

















medRxiv preprint doi: <https://doi.org/10.1101/2020.06.23.20138081>; this version posted June 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



medRxiv preprint doi: <https://doi.org/10.1101/2020.06.23.20118081>; this version posted June 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Odds Ratio (95% CI) for COVID-19 infection (RT-PCR positive or seropositive)



medRxiv preprint doi: <https://doi.org/10.1101/2020.06.25.20113061>; this version posted June 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

